The September quarter was somewhat disappointing. What does the future hold. Perhaps the AGM may have some positive news in 2 weeks? It would be good to snare another hospital contract. I was excited re VascuCel as compared to the CardioCel by virtue to the 180,000 ops in the USA annually. However the progress is slow and the margins are not great. Cardiocel 3D is the great hope still. No opposition, unique and selling at a high margin. Europe is asleep but I believe that they should concentrate on the Childrens hospital there and sell Neo and the 3D product. Its where the money is. Why is it taking so long to get these products into Europe when we have approval for the initial Adapt material product?
Ann: Admedus announces facility agreement with PFG, page-177
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.90 |
Change
0.140(1.19%) |
Mkt cap ! $248.6M | |||
| Open | High | Low | Value | Volume |
| $11.98 | $12.00 | $11.51 | $26.46K | 2.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 531 | $11.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.90 | 524 | 3 |
View Market Depth
| Last trade - 10.23am 08/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |